In a report released today, Matthew Taylor from Jefferies assigned a Buy rating to Insulet (PODD – Research Report), with a price target of ...

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM ...

MetLife Investment Management LLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 129.1% ...

A look at news events in June 2024. 1 - Israel's government says its conditions for ending the war with Hamas have not ...

The following table summarizes their recent ratings, shedding light on the ... heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical ...

In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a ...

Representatives from Breakthrough T1D, a leading global organization funding Type 1 diabetes research, visited Rice to learn ...

Insulet has persuaded a jury that rival South Korean company EOFlow stole trade secrets relating to its wearable insulin pump technology, awarding it a whopping $452 million in damages.

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of $305.00. The ...

pump manufacturers, regulatory authorities, and policymakers can best ensure the safety of new and long-standing users of insulin pumps as the technology continues to develop. We gathered evidence ...